Trending Tickers Today: Hims & Hers, BlackRock, Shell, and GSK Draw Investor Attention
On March 9, 2026, markets lit up with heavy trading tickers activity as investors zeroed in on a handful of standout stocks. Shares of Hims & Hers Health (HIMS) jumped sharply after news broke of a major distribution partnership with a leading weight‑loss drug maker that ended recent legal tensions. Meanwhile, seasoned giants like BlackRock attracted attention as broader credit markets faced pressure and dividend moves made headlines.
Energy heavyweight Shell also outperformed peers, rising despite broader market headwinds, and pharmaceutical leader GSK kept traders engaged with steady performance data. Today’s trending tickers reflect shifts in healthcare, finance, energy, and biopharma, making this a must‑watch session for market participants.
Hims & Hers Health: What’s Behind the Big Surge?
What Triggered the Massive Rally in HIMS Stock?
On March 9, 2026, Hims & Hers Health (NYSE: HIMS) saw its share price jump sharply, up around 40-50% in one session, which made it one of the most watched stocks in the market today. Multiple reports point to a reported deal with Novo Nordisk in which the Danish drug maker agreed to sell its branded weight‑loss medications on Hims & Hers’ platform and dropped a recent patent lawsuit against the company.
This change in relationship moved the narrative from legal risk to strategic partnership. Investors reacted strongly when Novo agreed to carry drugs like Ozempic and Wegovy on Hims’ telehealth platform, eliminating the previous legal cloud and opening a growth path in the highly lucrative GLP‑1 medication market.
Analysts also responded with rating activity on March 9. For example, Needham upgraded Hims & Hers to a Buy, marking a shift in sentiment. Meyka AI gave HIMS a B+ grade, indicating solid growth potential tempered by some caution due to mixed analyst views.
What Forecasts & Technical Signals are Available?
According to existing analyst price targets compiled from market data, the average target for HIMS is around $22.26, with a high estimate near $35.00 and a low near $12.50, suggesting wide variance in expectations.
This gap reflects uncertainty in execution and valuation. Traders should also consider that Meyka’s data and other technical indicators point to heightened volatility around current levels, where breakouts or pullbacks could occur quickly.
In short, HIMS’ recent move was driven by renewed pharma partnership news, but underlying strength will depend on the execution of growth initiatives and subscriber expansion.
BlackRock: Why This Asset Manager Is in Focus?
What Is Happening With BlackRock’s Stock Now?
BlackRock, Inc. (NYSE: BLK) has drawn fresh investor attention amid unusual developments in its private credit business. In early March 2026, the firm capped withdrawals at 5% from a major private credit vehicle after redemption requests exceeded that limit, highlighting liquidity pressures in the broader private credit market.
This decision was significant because it was among the first times BlackRock applied such restrictions. Shares subsequently declined sharply, with some reports showing declines of over 7% as investors weighed the implications.
What Analyst Views and Broader Signals Say?
Despite the near‑term weakness, long‑term fundamentals remain diversified. BlackRock’s assets under management hit a record ~$14 trillion in late 2025, with inflows driven by ETF and private markets growth.
Additionally, institutional filings show some funds increasing positions in BLK, and the company continues dividend payouts, which can appeal to long‑term income investors.
However, private credit stress has renewed risk concerns, particularly regarding illiquid loan portfolios and redemption pressure in alternative asset vehicles.
Key takeaway: BlackRock’s trending status reflects a tug‑of‑war between structural strength in ETF and index businesses and emerging weakness in private credit exposures.
Shell: Energy Sector Strength Amid Global Volatility
How Is Shell Performing Recently?
Shell plc (SHEL) has been among the better‑performing major energy stocks. On March 9, 2026, Shell’s shares rose roughly 2%, outperforming broader indices even as markets overall traded mixed.
This performance reflects a strong interest in energy names against a backdrop of elevated crude oil prices. Geopolitical tensions, especially concerns around supply from the Middle East, played a role in keeping energy prices elevated, pushing investors toward integrated oil and gas producers.
What are Analyst Targets & Sector Outlook?
Financial firms, including JPMorgan, updated price targets for Shell recently, boosting forecasts. One example saw a target raised to 3,600 GBp, reinforcing an heigherweight stance due to expected resilience in energy markets.
Investors often view Shell as a dividend‑rich, defensive energy play, especially during periods of macro uncertainty. While earnings projections suggest some headwinds in refining margins, integrated producers with LNG and upstream exposure can benefit from higher global oil prices lingering longer than anticipated.
GlaxoSmithKline (GSK): Licensing Deal Sparks Interest
What Was the Recent GSK News?
GlaxoSmithKline plc (GSK) stock has been trending recently due to licensing agreements around its investigational drug linerixibat. On March 9, 2026, GSK announced a global licensing deal with Italian pharma firm Alfasigma, valuing potential payments at up to $690 million.
Under the terms, GSK receives $300 million upfront and additional payments upon approvals, such as a U.S. FDA decision expected by March 24, 2026, plus tiered royalties on global sales.
How Did the Stock React?
Shares of GSK edged higher on the news, rising around 1.8% in some markets. Investors seem focused on how this licensing arrangement accelerates the monetization of assets that may otherwise sit longer on GSK’s balance sheet. However, some trading activity showed shares slipping slightly despite the deal, perhaps due to profit‑taking or broader market dynamics.
What Does This Mean for GSK’s Pipeline?
The Linerixibat deal underscores GSK’s strategy of monetizing later‑stage assets while focusing internal resources on priority areas such as liver disease innovation. Combined with other pipeline investments and acquisitions in 2026, GSK continues to reshape its portfolio.
Bottom Line
Today’s trending tickers highlight shifting market themes: telehealth growth and strategic partnerships for Hims & Hers, risk and resilience in BlackRock’s diversified businesses, energy strength in Shell, and pipeline monetization at GSK.
These movements reflect a market adapting to geopolitical pressures, regulatory changes, and evolving sector fundamentals. For active investors, tracking catalysts and structural drivers behind these trends is key to informed positioning.
Frequently Asked Questions (FAQs)
HIMS stock shot up sharply on March 9, 2026, after reports that Novo Nordisk agreed to sell its branded weight‑loss drugs on the Hims platform. This ended a legal dispute over copycat products and shifted sentiment from risk to growth potential. Investors reacted positively, pushing the stock up about 40% in one session.
BlackRock’s stock pulled back after the firm limited withdrawals from its large private credit fund in early March 2026. Redemption requests spiked, causing concerns about liquidity in this less liquid debt market and weighing on investor confidence.
Shell’s shares have held steady and gained some ground recently as oil prices stay elevated due to global supply concerns. On March 9, 2026, Shell outperformed many peers, rising while broader markets were weaker, as investors sought energy stocks with strong cash flow.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)